Multiple myeloma: Takeda presents data from phase 3 TOURMALINE-MM1 study for NINLARO

Takeda Pharmaceutical Company Limited has announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing… Source link